attyloid’s sFIDA technology unveils potential non-invasive biomarker for Alzheimer’s Disease
We are excited to announce a groundbreaking discovery at attyloid, made possible through our proprietary sFIDA technology, with the potential to significantly enhance Alzheimer’s disease (AD) diagnostics. Our study demonstrates that amyloid β (Aβ) aggregates—key indicators of AD—are detectable in human feces, offering a promising non-invasive biomarker for the disease.
Aβ misfolding and aggregation, along with Tau protein tangles, are hallmarks of Alzheimer’s disease progression. Until now, detecting these markers in a non-invasive manner has posed a challenge. In this study, we hypothesized that Aβ aggregates might be cleared from the brain and body into the gut, allowing for measurable detection in fecal samples.
Using sFIDA technology, we were able to precisely determine Aβ aggregate concentrations in fecal samples from 26 Alzheimer’s patients and 31 healthy controls. Our technology, designed for ultrasensitive detection of protein aggregates, revealed significantly elevated Aβ concentrations in AD patients compared to healthy controls, achieving a specificity of 90.3%.
This highlights the power of our sFIDA technology, uniquely capable of detecting minute amounts of protein aggregates with exceptional accuracy. These findings suggest that Aβ aggregates in feces could serve as a non-invasive biomarker for Alzheimer’s disease, marking an important step forward in diagnostic capabilities. Ongoing research will explore whether these aggregates are secreted via the liver and bile or originate directly from the enteric nervous system.